skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Glioblastoma multiforme: treatment by large dose fraction irradiation and metronidazole

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

In an attempt to overcome the possible radioresistance of glioblastoma multiforme related to the large shoulder on the in vitro survival curves and to sensitize hypoxic tumor cells, a treatment protocol was instituted at Yale University Medical Center and affiliated hospitals, using large dose fraction irradiation therapy in conjunction with the hypoxic cell sensitizer metronidazole. Nineteen patients with biopsy-confirmed, previously untreated, cerebral grade IV glioblastoma multiforme were, following surgery, irradiated once a week at 600 rad per fraction, 3.5 to 4 hours after ingestion of metronidazole, 6 gm/m/sup 2/. A total of 7 treatments were employed, with all patients maintained on antiseizure medications and corticosteroids. Metronidazole levels were determined prior to each treatment and patients were followed closely clinically and with serial computerized tomography (CT) scans. The treatment was well tolerated, in general, with no untoward side effects related to the high dose fraction irradiation. The majority of the patients experienced varying degrees of gastrointestinal upset lasting up to several hours following metronidazole administration. Three patients died of pulmonary emboli. One patient experienced moderately severe ototoxicity. A median survival of 9.4 months was obtained for all 19 patients, suggestive of a prolongation of survival compared to historical controls treated with conventionally fractionated radiation or with unconventional radiation fractionation schemes and metronidazole or misonidazole.

Research Organization:
Yale Univ. School of Medicine, New Haven, CT
OSTI ID:
6724368
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 8:3/4
Country of Publication:
United States
Language:
English

Similar Records

Phase 1/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513
Journal Article · Wed Apr 01 00:00:00 EDT 2015 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:6724368

GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme: A Retrospective Multi-Institutional Pilot Study
Journal Article · Tue May 01 00:00:00 EDT 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:6724368

Superfractionation in glioblastoma multiforme--Results of a phase II study
Journal Article · Fri Oct 01 00:00:00 EDT 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6724368